Chardan Raised Its REGENXBIO Price Target From $85 to $90 On News Co.'s Partner, AveXis, Was Bought By Novartis, Believing This Could Support M&A Interest in RGNX & Suggesting 'Consensus is underestimating the impact of AVXS-101 royalites on REGENXBIO'